China Calls for Fairness for Its Enterprises as Macron Asks EU to Restrict Chinese Investment Jun 26, 2017 Others
DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM Jun 23, 2017 Others
Preferred Dental Technologies Inc. announces it’s EAS product is being included in presentation Jun 23, 2017 Others
DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma (“GBM”) at SNO’s Pediatric Neuro-Oncology Basic and Translational Research Conference Jun 17, 2017 Mining
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results May 19, 2017 Technology
Luminor Medical Technologies Acquiring Exclusive Canadian & Jamaican Licenses for Cannabis Products – Video Available on Investmentpitch.com May 12, 2017 Technology
DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM) May 12, 2017 Technology
DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS) May 9, 2017 Energy
